Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Table of Contents . Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Select Market Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Robert Walker - Senior Vice President and Chief Medical Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMo ...

Key TakeawaysNovavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results.The company has cut its guidance multiple times this year, and the new range is below the analyst consensus.On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.  The COVID-19 and flu vacci ...

| --- | --- | --- | |-------------------------------------|---------------------|-------| | | Third quarter 2024 | | | | | | | operational | financial results & | | | highlights | | | | Nasdaq: NVAX \| November 12th, 2024 | | | © 2024 NOVAVAX. All rights reserved. 1 Cautionary note regarding forward-looking statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," ...

Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.64%. A quarter ago, it was expected that this vaccine maker would post earnings of $1.82 per share when it actually produced earnings of $0.99, delivering a surprise of -45.60%.Over the last four quarters, the company has surpa ...

Press Release Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights • U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates • Achieved total revenue of $85 million in the third quarter of 2024 • Ended the third quarter of 2024 with $1 billion in cash and receivables • Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individua ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivables Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older Outlined R&D strategy based on its proven technology platform Updates full year ...

Key TakeawaysNovavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.Regulators stopped testing last month as one patient had a serious adverse event after taking the shot.The company said further information supported its contention that the vaccine did not cause the problem, and it will now move to resume its research as soon as possible. Novavax (NVAX) shares edged higher Monday after the drugmaker announ ...

Novavax (NVAX) is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported quarter, the company’s earnings missed estimates by 45.60%.The Zacks Consensus Estimate for sales is pegged at $57.3 million while that for earnings is pinned at a loss of 87 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Factors Shaping NVAX’s Upcoming ResultsAlthough Novavax secured the FDA’s authorization for an updated version of its protei ...